Oct 4, 2010 | Laboratory News, Laboratory Pathology, Laboratory Testing
Much medical laboratory testing done in support of cholesterol and cardiovascular management
In many cases, a prescription for a therapeutic drug is the result of a medical laboratory test. Thus, pathologists and clinical laboratory managers might be interested in knowing which drugs topped the 2010 IMS Health Incorporated list for most-prescribed pharmaceuticals.
Topping the list is the combo drug hydrocodone acetaminophen, which is primarily taken to control pain. This blended opiate/analgesic is marketed under various brand names, such as Vicodin, depending on the manufacturer and quantity of the individual drugs.
(more…)
Sep 23, 2010 | Laboratory Pathology, News From Dark Daily
Some U.S. laboratories already ramping up their LIS resources to meet demand for LIS-to-EMR interfaces
Clinical laboratory managers and pathology groups need to prepare for what is expected to be a tsunami of requests by physicians who want their newly-implemented electronic medical record (EMR) systems to be interfaced with their laboratory’s LIS. This approaching tsunami is a consequence of the billions in federal incentive payments designed to encourage doctors to adopt EMRs.
It means lab managers and pathologists must actively prepare their medical laboratory to step up and support the “meaningful use” needs of client physicians. As mandated by the HITECH Act, healthcare providers are required to engage in “meaningful” patient health information (PHI) exchanges. Because more than 400,000 physicians will implement electronic medical records (EMR) in the next 60 months, labs should not delay in establishing a strategy.
(more…)
Sep 15, 2010 | Laboratory News, Laboratory Pathology
Price of 2.5 times revenue makes this a high price for a clinical laboratory
Monday, Laboratory Corporation of America (NYSE: LH) agreed to purchase Genzyme Genetics Corp’s. (NASDAQ: GENZ) fetal genetics and oncology testing division for $925 million in cash. Genzyme has shopped its neo-natal genetic testing business since last year.
LabCorp is paying a purchase price that is 2.5 times Genzyme’s $371 million in annual revenue. This is one of the highest prices paid for a clinical pathology laboratory company since Quest Diagnostics Incorporated (NYSE: DGX), paid about 2.5 times revenue for Ameripath, Inc. in March 2007. In that transaction, Quest Diagnostics paid about $2 billion for Ameripath, which had annual revenues approaching $800 million at the time of sale.
(more…)
Sep 13, 2010 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Digital pathology is major trend in the clinical pathology laboratory industry
Among the three dominant trends in anatomic pathology informatics, digital pathology is expected to be of the highest interest to the attendees at this year’s Pathology Informatics 2010 annual conference, which takes place in Boston on September 19-22.
“More pathologists are paying attention to digital pathology because of the swift advances in the technology in recent years,” stated Bruce Friedman, Active Emeritus Professor of Pathology at the University of Michigan Medical School and President of the Pathology Education Consortium (PEC) is a conference organizer. “For example, new digital scanners make it faster and cheaper to produce a whole slide image that has rich detail.
(more…)
Sep 9, 2010 | Laboratory Pathology, Management & Operations
Special clinical laboratory manager training to take place in four cities this fall
Predictions are that clinical laboratories and pathology groups across the nation will face a growing and serious shortage of skilled managers during the next 24 months. There are two primary reasons why this acute shortage of capable lab managers is soon to develop.
First, the oldest baby boomers turn 65 in January and the long-awaited wave of retirements will begin. This means the most experienced staff members in the medical laboratory—managers at the bench level, the section, and the department—will vacate those positions of responsibility. As these managers depart, the lab loses their decades of experience, along with their invaluable organizational knowledge.
(more…)
